81. Congenital adrenal hyperplasia Clinical trials / Disease details

Clinical trials : 88 / Drugs : 90 - (DrugBank : 23) / Drug target genes : 12 - Drug target pathways : 68

3 trials found

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT03760835 (ClinicalTrials.gov)	August 11, 2016	9/11/2018	Congenital Adrenal Hyperplasia Once Daily Hydrocortisone Treatment	Congenital Adrenal Hyperplasia: Innovative Once Daily Dual Release Hydrocortisone Treatment	Congenital Adrenal Hyperplasia	Drug: Conventional Glucocorticoids (immediate release hydrocortisone, cortisone acetate, prednisone, prednisolone, dexamethasone);Drug: Dual release hydrocortisone (plenadren)	Federico II University	NULL	Recruiting	18 Years	N/A	All	150	Phase 4	Italy
2	NCT01771328 (ClinicalTrials.gov)	February 2013	10/1/2013	Continuous Subcutaneous Hydrocortisone Infusion in Congenital Adrenal Hyperplasia	Continuous Subcutaneous Hydrocortisone Infusion in Congenital Adrenal Hyperplasia	Adrenal Hyperplasia, Congenital	Drug: Hydrocortisone;Drug: Cortisone acetate	Haukeland University Hospital	NULL	Recruiting	18 Years	60 Years	Both	20	Phase 2	Norway
3	EUCTR2011-005822-23-NO (EUCTR)	16/10/2012	25/02/2013	A trial comparing continuous subcutaneous hydrocortisone therapy with conventional oral glucocorticoid therapy in congenital adrenal hyperplasia	CONTINUOUS SUBCUTANEOUS HYDROCORTISONE INFUSION IN CONGENITAL ADRENAL HYPERPLASIA	Congenital adrenal hyperplasia (CAH) MedDRA version: 14.1;Level: LLT;Classification code 10010323;Term: Congenital adrenal hyperplasia;System Organ Class: 100000004850;Therapeutic area: Diseases [C] - Hormonal diseases [C19]	Trade Name: Solu-Cortef Trade Name: Cortison Trade Name: Prednisolone	Haukeland University Hospital	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes			Norway